Nomura Holdings’s Summit Therapeutics SMMT Stock Holding History

Nomura Holdings’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.64M	Sell	112,359 -201,622	-64%	-$3.58M	﹤0.01%	1184
2026 Q1	$5.95M	Sell	313,981 -228,253	-42%	-$3.69M	0.02%	590
2025 Q4	$9.48M	Sell	542,234 -506,693	-48%	-$9.53M	0.01%	532
2025 Q3	$21.7M	Buy	1,048,927 +1,004,971	+2,286%	+$24.4M	0.03%	299
2025 Q2	$935K	Buy	+43,956	New	+$1M	﹤0.01%	1022
2024 Q4	–	Sell	-18,967	Closed	-$415K	–	2381
2024 Q3	$415K	Buy	+18,967	New	+$265K	﹤0.01%	1290
2023 Q2	–	Sell	-47,971	Closed	-$83.9K	–	1610
2023 Q1	$83.9K	Buy	+47,971	New	+$131K	﹤0.01%	1309

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nomura Holdings's SMMT Position: Q2 2026 in Review

Nomura Holdings reduced its Summit Therapeutics (SMMT) stake by 64% in Q2 2026, selling an estimated $3.58M and leaving 112,359 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1184.

Nomura Holdings first reported a position in SMMT in Q1 2023 and has held it in 7 quarters since. The position peaked at $21.7M in Q3 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Nomura Holdings held 112,359 shares of Summit Therapeutics worth $1.64M as of Q2 2026.
Nomura Holdings sold 201,622 Summit Therapeutics shares in Q2 2026, an estimated $3.58M.
Summit Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q2 2026, its #1184 holding.
Nomura Holdings first reported a position in Summit Therapeutics in Q1 2023 and has held it in 7 quarters since.
Nomura Holdings's Summit Therapeutics position peaked at $21.7M in Q3 2025.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.